Home Support ISMP Newsletters Webinars Report Errors Educational Store Consulting FAQ Tools About Us Contact Us
ISMP Facebook

Kapidex-Casodex confusion

From the August 13, 2009 issue

There have been reported instances of medication errors due to name confusion between KAPIDEX (dexlansoprazole) and CASODEX (bicalutamide). Both written and verbal prescriptions have been dispensed in error. Kapidex is indicated for healing of erosive esophagitis, maintenance of healed erosive esophagitis, and treatment of symptomatic nonerosive gastroesophageal reflux disease (GERD). It is available as 30 mg and 60 mg delayed-release capsules for oral administration. Casodex is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of stage D2 metastatic carcinoma of the prostate. Casodex is available as 50 mg tablets for oral administration. Patients who receive either drug in error could be unnecessarily subjected to unintended effects and/or adverse events. Specifically, Casodex is contraindicated in women. To reduce the potential for medication errors, please take time to verify written or verbal orders and build an alert in your computer system. If you are a prescriber, please include the drug’s purpose on prescriptions.  


Acute Care Main Page
Current Issue
Past Issues
Highlighted articles
Action Agendas - Free CEs
Special Error Alerts
Newsletter Editions
Acute Care
Long Term Care
Home | Contact UsEmployment  | Legal Notices | Privacy Policy | Help Support ISMP
Med-ERRS Med-ERRS | MSOMedication Safety Officers Society | Consumer Medication SafetyFor consumers
 ISMP Canada ISMP Canada | ISMP Spain ISMP Spain | ISMP Brasil ISMP Brasil | International Group | Pennsylvania Patient Safety Authority

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797,  Fax: (215) 914-1492
© 2018 Institute for Safe Medication Practices. All rights reserved